Adjuvant Surgery in Testicular Cancer Patients Undergoing Postchemotherapy Retroperitoneal Lymph Node Dissection
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
To evaluate the clinicopathologic characteristics of patients undergoing adjuvant surgery during postchemotherapy retroperitoneal lymph node dissection (PC-RPLND).
From 2004 to 2010, 85 testicular cancer patients underwent PC-RPLND by a single surgeon (S.D.). A bilateral template approach was utilized with nerve-sparing technique whenever feasible. The clinicopathologic and outcome of patients who underwent removal of any organ or structure during PC-RPLND were reviewed.
Of 85 patients undergoing PC-RPLND, 28 (33%) required adjuvant procedures. Thirteen (15%) required vascular procedures including cavotomy/caval resection in 6, aortic resection in 8, common iliac vessels resection in 4, and renal vessels resection/reimplant in 2. Twelve patients (14%) required adjuvant nephrectomy (ten of 12 left-sided). There was one ureteral resection with appendiceal substitution, one partial duodenectomy, two cholecystectomy, two thoracotomies, four liver resection/biopsy, and one neck dissection. There were eight early complications (28%), including vocal cord paralysis, brachial plexus injury, lower extremities compartment syndrome, thigh numbness, upper gastrointestinal bleeding, retroperitoneal hematoma, and alcohol withdrawal. No perioperative death was reported. Retroperitoneal pathology revealed mature teratoma in 11 patients (39%), fibrosis in 8 (28%), and viable germ cell tumor (GCT) in 9 (32%). A total of 75, 82, and 66% of patients with fibrosis, teratoma, and viable GCT, respectively, had no evidence of recurrence at a mean follow-up of 18 months.
Many patients undergoing PC-RPLND require adjuvant surgery, including vascular procedures and nephrectomy. The excellent outcomes associated with low operative morbidity and mortality validates such aggressive surgical approaches performed by experienced surgeons.
- Stephenson AJ, Tal R, Sheinfeld J. Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol. 2006;176:1996–9. CrossRef
- Kollmannsberger C, Daneshmand S, Hansen E, et al. Testis cancer. In: Hong WK, Bast RC, Hait WN, et al., editors. Cancer medicine. 8th ed. Shelton: PMPH-USA; 2010. p. 1263–1288.
- Carver BS, Motzer RJ, Bajorin D, Stasi J, Bosl GJ, Sheinfeld J. Post-chemotherapy retroperitoneal lymph node dissection for non-seminomatous germ cell tumors: the impact of time. J Clin Oncol. 2005;23(16 Suppl., Pt. 1 of 2):4581. CrossRef
- Donohue JP, Leviovitch I, Foster RS, et al. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol. 1998;16:65–71.
- Nash PA, Leibovitch I, Foster RS, et al. En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes. J Urol. 1998;159:707–10. CrossRef
- Heidenreich A, Ohlmann C, Hegele A, et al. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol. 2005;47:64–71. CrossRef
- Donohue JP, Foster RS. Management of retroperitoneal recurrences. Seminoma and nonseminoma. Urol Clin North Am. 1994;21:761–72.
- Christmas TJ, Smith GL, Kooner R. Vascular interventions during post-chemotherapy retroperitoneal lymph-node dissection for metastatic testis cancer. Eur J Surg Oncol. 1998;24:292–7. CrossRef
- Duty B, Daneshmand S. Resection of the inferior vena cava without reconstruction for urologic malignancies. Urology. 2009;74:1257–62. CrossRef
- Duty B, Daneshmand S. Venous resection in urological surgery. J Urol. 2008;180:2338–42. CrossRef
- Beck SD, Lalka SG. Long-term results after inferior vena caval resection during retroperitoneal lymphadenectomy for metastatic germ cell cancer. J Vasc Surg. 1998;28:808–14. CrossRef
- Mosharafa AA, Foster RS, Koch MO, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol. 2004;171:1839–41. CrossRef
- Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol. 1993;11:1294–9.
- Sheinfeld J. Risks of the uncontrolled retroperitoneum. Ann Surg Oncol. 2003;10:100–1. CrossRef
- Baniel J, Foster RS, Rowland RG, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol. 1995;153:976–80. CrossRef
- Baniel J, Sella A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin Surg Oncol. 1999;17:263–7. CrossRef
- McKiernan JM, Motzer RJ, Bajorin DF, et al. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology. 2003;62:732–6. CrossRef
- Adjuvant Surgery in Testicular Cancer Patients Undergoing Postchemotherapy Retroperitoneal Lymph Node Dissection
Annals of Surgical Oncology
Volume 19, Issue 7 , pp 2388-2393
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Urology, Norris Cancer Center, University of Southern California, Los Angeles, CA, USA
- 2. Section of Hematologic/Oncology, Department of Medicine, Virginia Mason Medical Center, Seattle, WA, USA